Hospital
Novant Health Thomasville Medical Center, LLC
Novant Health Thomasville Medical Center, LLC was paid $15.32M by Medicaid between Jan 2018 and Dec 2024, across 120 billing codes. Its largest line is 99284, emergency room visit (serious) — 26% of everything it billed.
33Billing provider infoNOVANT HEALTH THOMASVILLE MEDICAL CENTER, LLC
THOMASVILLE, NC 27360
THOMASVILLE, NC 27360
33aNPI1801848767assigned 05/17/2006
33bProvider typePsychiatric Hospital Unit
28Total paid$15.32M
24GClaims364,597
24DCodes billed120
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Psychiatric Hospital Unit providers in North Carolina
Rank by total paid#2 of 7
Median peer was paid$295K
This provider vs. median52×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 40,893 | $1.38M | |
| 2019 | 39,131 | $1.30M | |
| 2020 | 32,289 | $821K | |
| 2021 | 40,136 | $2.12M | |
| 2022 | 64,839 | $3.16M | |
| 2023 | 73,922 | $3.08M | |
| 2024incomplete | 73,387 | $3.45M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 26% | 18,500 | 17,020 | $4.04M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 23% | 29,630 | 27,919 | $3.51M |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 9.1% | 8,584 | 8,033 | $1.40M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 8.3% | 5,097 | 4,524 | $1.27M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.8% | 1,525 | 1,428 | $889K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.6% | 6,574 | 6,249 | $405K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.0% | 40,480 | 34,524 | $300K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.0% | 9,144 | 8,347 | $299K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.9% | 6,255 | 5,192 | $298K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.9% | 15,645 | 12,913 | $292K |
| 80053 | Comprehensive metabolic panel | 1.8% | 33,913 | 29,224 | $279K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.6% | 9,942 | 8,703 | $252K |
108 more codes
| 71046 | Radiologic examination, chest; 2 views | 1.6% | 5,365 | $241K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1.5% | 8,232 | $224K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.4% | 5,664 | $222K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.2% | 1,312 | $188K |
| 71045 | Radiologic examination, chest; single view | <1% | 2,984 | $128K |
| J3490 | Unclassified drugs | <1% | 75,564 | $112K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,864 | $105K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 1,723 | $55K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,616 | $46K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,080 | $46K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,012 | $39K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,824 | $39K |
| 81025 | <1% | 4,576 | $33K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 8,726 | $33K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,727 | $32K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,685 | $31K |
| 84484 | <1% | 2,661 | $30K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 276 | $24K |
| 84703 | <1% | 2,367 | $24K | |
| 87430 | <1% | 1,483 | $24K | |
| G0378 | Hospital observation service, per hour | <1% | 541 | $23K |
| 83735 | <1% | 3,266 | $21K | |
| 81001 | <1% | 5,591 | $18K | |
| 82728 | <1% | 1,390 | $18K | |
| 83690 | <1% | 2,292 | $17K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 293 | $16K |
| 36591 | <1% | 1,302 | $14K | |
| 72020 | <1% | 466 | $14K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 612 | $14K |
| 87070 | <1% | 1,160 | $14K | |
| 59025 | Fetal non-stress test | <1% | 230 | $13K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 246 | $13K |
| 80299 | <1% | 722 | $13K | |
| 83550 | <1% | 1,382 | $11K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 3,352 | $10K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 12 | $10K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 195 | $9K |
| 83540 | <1% | 1,406 | $8K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 128 | $8K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 607 | $8K |
| J9190 | Injection, fluorouracil, 500 mg | <1% | 256 | $6K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 13 | $6K |
| 96367 | <1% | 191 | $6K | |
| 81003 | <1% | 2,299 | $6K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 202 | $5K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 150 | $5K |
| 80143 | <1% | 261 | $5K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 67 | $5K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 31 | $5K |
| 82607 | <1% | 366 | $5K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 293 | $5K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 12 | $4K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 266 | $4K |
| 82746 | <1% | 333 | $4K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 12 | $4K |
| 88304 | <1% | 65 | $4K | |
| 96416 | <1% | 95 | $4K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,970 | $4K |
| 80179 | <1% | 234 | $4K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 164 | $3K |
| J2704 | Injection, propofol, 10 mg | <1% | 104 | $3K |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 218 | $3K |
| J7999 | Compounded drug, not otherwise classified | <1% | 316 | $3K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 140 | $2K |
| 83605 | <1% | 175 | $2K | |
| 82533 | <1% | 220 | $2K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 595 | $2K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 242 | $2K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 212 | $1K |
| 96415 | <1% | 54 | $1K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 302 | $1K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 32 | $1K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 32 | $1K |
| 76000 | <1% | 37 | $1K | |
| 73562 | <1% | 14 | $1K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 29 | $963.77 |
| 82550 | <1% | 141 | $928.22 | |
| 85610 | <1% | 262 | $831.64 | |
| J0640 | Injection, leucovorin calcium, per 50 mg | <1% | 16 | $800.47 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 183 | $765.98 |
| 96523 | <1% | 36 | $742.50 | |
| 83615 | <1% | 111 | $707.78 | |
| 84153 | <1% | 46 | $691.27 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 84 | $678.76 |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 24 | $655.82 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 168 | $632.29 |
| 84702 | <1% | 51 | $545.00 | |
| 94729 | <1% | 26 | $472.10 | |
| J8597 | Antiemetic drug, oral, not otherwise specified | <1% | 1,134 | $415.68 |
| 94727 | <1% | 14 | $410.76 | |
| 83880 | <1% | 15 | $375.86 | |
| 94060 | <1% | 14 | $363.12 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 14 | $336.27 |
| 82803 | <1% | 16 | $300.73 | |
| 85379 | <1% | 25 | $298.16 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 13 | $290.76 |
| 85730 | <1% | 48 | $286.56 | |
| 84439 | <1% | 53 | $191.69 | |
| 84550 | <1% | 45 | $186.15 | |
| 87420 | <1% | 14 | $185.64 | |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 1,667 | $183.13 |
| 87077 | <1% | 13 | $171.60 | |
| 85027 | <1% | 35 | $163.59 | |
| 87210 | <1% | 14 | $100.75 | |
| 84100 | <1% | 21 | $88.30 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 39 | $47.15 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 16 | $0.49 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 14 | $0.12 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBROWN, CHRISTOPHER (FACILITY PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| San Francisco Critical Care Med Group INC | San Francisco, CA | $1.51M |
| Shirkey Diversified Health Services, INC. | Richmond, MO | $840K |
| Arctic Pathways, LLC | Fairbanks, AK | $368K |
| Focal Point Eyewear | Philadelphia, PA | $173K |
| Doc Browns INC | Wantagh, NY | $111K |
| Brown Family Chiropractic, PC | Quincy, MA | $40K |
| Brown Eye Care Associates MD PA | Teaneck, NJ | $35K |
| Springfield Medical Assoc PSC | Springfield, KY | $32K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.